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Abstract: Cystic fibrosis (CF) is a systemic genetic disease that leads to pulmonary and digestive
disorders. In the majority of CF patients, the intestine is the site of chronic inflammation and
microbiota disturbances. The link between gut inflammation and microbiota dysbiosis is still poorly
understood. The main objective of this study was to assess gut microbiota composition in CF children
depending on their intestinal inflammation. We collected fecal samples from 20 children with CF.
Fecal calprotectin levels were measured and fecal microbiota was analyzed by 16S rRNA sequencing.
We observed intestinal inflammation was associated with microbiota disturbances characterized
mainly by increased abundances of Staphylococcus, Streptococcus, and Veillonella dispar, along with
decreased abundances of Bacteroides, Bifidobacterium adolescentis, and Faecalibacterium prausnitzii.
Those changes exhibited similarities with that of Crohn’s disease (CD), as evidenced by the elevated
CD Microbial-Dysbiosis index that we applied for the first time in CF. Furthermore, the significant
over-representation of Streptococcus in children with intestinal inflammation appears to be specific
to CF and raises the issue of gut–lung axis involvement. Taken together, our results provide new
arguments to link gut microbiota and intestinal inflammation in CF and suggest the key role of the
gut–lung axis in the CF evolution.
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1. Introduction
Cystic fibrosis (CF) is a genetic disorder caused by mutations in the Cystic Fibrosis Transmembrane
Conductance Regulator gene (CFTR), leading to viscous secretions accumulating on epithelial surfaces
in both the lungs and the gastrointestinal tract [1]. In recent decades, improved patient care in
the management of pulmonary disease has led to an older CF population with new complications,
including intestinal disorders [2]. However, some CF gastrointestinal complications such as chronic
inflammation, gut microbiota disruption, and increased risk of gastrointestinal malignancies remain
poorly understood [3–6].
Gut microbiota has been recently shown to be associated with the human health and diseases
including CF [7]. Its composition is clearly different in CF patients, with a decrease in specific
bacteria such as Bifidobacterium spp., Eubacterium spp., Clostridium spp., and Faecalibacterium prausnitzii,
and the emergence of opportunistic pro-inflammatory bacteria such as Escherichia coli and Eubacterium
biforme [4,8–11]. In CF, this disturbed microbiota, usually named “dysbiosis”, stems from multiple
factors including hydro electrolytic disruptions of the intestinal secretions, slower gastrointestinal
transit time [12], drug uses, impaired innate immunity in the gut [13,14], and hypercaloric diet [15,16],
and appears to be correlated with the severity of the CFTR mutations [11].
Furthermore, chronic intestinal inflammation is present in the majority of CF patients, even in the
absence of digestive symptoms [17]. Inflammation is characterized by an infiltrate of the lamina propria
by mononuclear cells expressing inflammation markers (such as ICAM-1, CD-25, IL-2, IFNγ) associated
with Crohn’s-like endoscopic lesions of the mucosa (edema, erythema, or ulcerations) [3,18,19].
To better assess intestinal inflammation, Bruzzese et al. have adapted in CF the fecal calprotectin
measurement, previously used as a non-invasive digestive inflammation biomarker in inflammatory
bowel disease (IBD) [20]. Fecal calprotectin level is significantly higher in CF patients compared to
healthy subjects [20–22].
The pathophysiology of intestinal inflammation is still unclear in CF. Very few studies have
focused on the link between intestinal microbiota composition and inflammation in CF, while this link
is well documented in IBD [23]. To our knowledge, only one study using next-generation sequencing
(NGS) of microbiota was dedicated to this issue and showed a positive correlation between E. coli
abundance and intestinal inflammation in CF children [24]. A recent study focused on the evolution
of intestinal microbiota and inflammation in CF patients treated with ivacaftor, a CFTR-modifying
therapy. An absence of intestinal inflammation was significantly associated with an increased
Akkermansia abundance [25].
As previous studies focused on mucosal inflammation and microbiota in the gastrointestinal tract
of CF patients were highly limited [22,24], our aim was to investigate links between gut microbiome
and intestinal inflammation using NGS approach plus fecal calprotectin measurements, in a pediatric
CF population.
2. Materials and Methods
2.1. Study Design, Sample Collection, and Ethics Statement
Our observational prospective study took place at the Children’s Hospital of Bordeaux from
November 2015 to May 2018. The inclusion criteria were patient over 3 years of age with
well-documented CF associated with exocrine pancreatic insufficiency. The exclusion criteria were an
ongoing enrollment in therapeutic protocols, antibiotics, or probiotics courses during the two months
prior the inclusion or patients after organ transplantation.
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At the inclusion visit patients’ stool samples were collected and stored at −80 ◦C until use.
In parallel, patient clinical status was documented using demographic data, nutritional status
assessed by the Body Mass Index expressed as percent of the standard normalized by age (%BMI),
respiratory capacity measured by Forced Expiratory Volume in 1s expressed as percent predicted
(%FEV1), and microbial pulmonary colonization along with previous intravenous (IV), oral, or inhaled
antibiotic courses.
In addition, questionnaires focused on standardized assessments of quality of life (PedsQLTM 4.0
Generic Core Scale) and of digestive symptoms (PedsQLTM—Gastrointestinal Symptoms Scales 3.0)
were provided at no charge via the ePROVIDE™ online distribution process and filled for each child.
These questionnaires, validated for different age groups, include a self-assessment and a parental
evaluation. A score negatively correlated with the presence of symptoms was assigned from 0 to
100 to each item based on the collected responses. An average score was calculated for the main
questionnaire sections.
Finally, long-term evolution based on clinical monitoring two years after inclusion was recorded
for each child, based on %BMI and %FEV1 values at the follow-up visit, plus the corresponding
variations (estimated by the difference between %BMI or %FEV1 measures at two years and inclusion),
and the number of antibiotic courses during this period (IV, oral, inhaled, or any mode of administration
combined) (Table 1 and Supplementary Table S1).
Table 1. Characteristics of patients with and without intestinal inflammation.
No Inflammatory Group Inflammatory Group
Patient 13 (65%) 7 (35%)
Fecal calprotectin level 122 (91.0–149.0) 459 (324.5–925.0)
Age in years 9 (7.0–11.0) 8 (7.5-11.5)
Female 7 (53.9%) 3 (43%)
Mutations
- F508del homozygous 10 (77%) 4 (57%)
- F508del heterozygous 2 (15%) 3 (43%)
- Others 1 (8%) 0
%BMI † 97.6 (94.0–108.0) 98.3 (88.5–97.7)
%FEV1 †† 81(71.0–91.0) 76 (71.5–93.5)
Chronic pulmonary colonization
- P. aeruginosa 1 (8%) 0
- S. aureus 11 (85%) 7 (100%)
Previous IV antibiotic courses * 0 (0–2) 5 (0.5–10)
Quality of life
- Parents’ report 81.9 (76.5–88.4) 89.0 (86.7–90.4)
- Child’s report 83.9 (71.9–89.2) 85.1 (76.8–88.6)
Digestive symptoms ••
- Parents’ report 83.2 (80.6–90.7) 94.5 (93.6–95.0)
- Child’s report 84.5 (79.4–95.1) 91.2 (88.7–98.1)
Follow-up at 2 years
- %BMI † 96.6 (90.6–105.9) 97.6 (92.3–102.6)
- %BMI variation −0.5 (−3.8–1.5) −0.3 (-1.0–3.0)
- %FEV1 †† 84.0 (71.2–95.2) 83.5 (69.5–85.5)
- %FEV1 variation 1 (−21.0–8.5) 9 (-4.7–14.5)
- IV antibiotics 2.5 (0.0–5.2) 6.5 (5.2–9.2)
- Oral antibiotics 1.5 (0.0–3.2) 2 (2.0–2.7)
- Inhaled antibiotics + 1 (1.0–1.2) 2 (2.0–2.7)
- Total antibiotics + 5 (3.7–8.2) 11.5 (10.2–12.7)
Data are presented as n (%) or median (interquartile interval); Abbreviations: BMI, body mass index; FEV1, Forced
Expiratory Volume in 1s; IV, intravenous; + p < 0.05; † expressed as percent of the standard normalized by age;
†† expressed as percent predicted; * Evaluated using PedsQLTM Generic Core Scale 4.0; •• Evaluated using PedsQL™
Gastrointestinal Symptoms Scales 3.0.
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The present study was approved by the regional ethical committee “CPP Sud-Ouest et Outremer
III” (DC 2015/129). Informed consent was sought from study participants and their parents.
2.2. Measurements of Fecal Calprotectin
The fecal calprotectin assay was carried out using the GHSA kit (Eurobio, Courtabœuf, France).
In the absence of a specific threshold in CF, we applied a cut-off of 250 µg/g, recently validated to
predict an inflammatory flare associated with endoscopic lesions in IBD [26,27].
2.3. Microbiota Analysis
DNA extraction was performed using DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. The DNA samples were the used for V4 region of the
16S rRNA gene sequencing as previously described [28]. For specific analysis of S. oralis and total
bacteria population, droplet digital PCR (ddPCR) on the fecal DNA was performed, as described in the
Supplemental Information.
2.4. Sequencing and Bioinformatics Analysis
Next-generation sequencing was performed using Illumina MiSeq sequencer, and bioinformatic
analysis as described previously [28]. Alpha and beta diversity indexes were assessed using raw
Operational Taxonomic Unit (OTU) occurrence counts and a Non-Metric Multidimensional Scaling
(NMDS) ordination method with Bray-Curtis distance metric implemented by R package phyloseq,
respectively. Subsequent OTU filtering and analyses were performed with MicrobiomeAnalyst
(http://www.microbiomeanalyst.ca) [29]. OTUs were normalized by total sum scaling. Two groups
of patients were defined with low (<250 µg/g) and high (>250 µg/g) fecal calprotectin level and used
for DESeq2 [30] (Supplementary Table S2) and LEfSe [31] (Supplementary Table S3) analyses to find
differentially present taxa and microbiota markers, respectively. Raw data have been deposited in the
European Nucleotide Archive (ENA) sequence read archive (ENA accession number PRJEB28609).
2.5. Microbial Dysbiosis Index Evaluation
We estimated the Microbial Dysbiosis index (MD-index; Supplementary Table S4), a ratio between
relative abundance of increased and decreased bacteria recently proposed in Crohn’s disease (CD) [32].
2.6. Statistical Analysis
Differentially present taxonomic nodes between groups of patients were calculated using DESeq2
approach and a False Discovery Rate (FDR) < 0.05. LEfSe method was used to identify metagenomic
biomarkers [31]. Nonparametric Wilcoxon–Mann–Whitney test was used to compare quantitative
variables between groups. Correlations were calculated using Spearman method. Statistical analysis
was performed with R studio program (version 1.1.453 for WindowsTM); a p-value < 0.05 was considered
indicative of statistical significance.
3. Results
Intestinal inflammation is associated with more previous intravenous antibiotic courses in CF.
Twenty children with CF between 6 and 14 years of age were included; their main demographic
characteristics, clinical and microbiological data are summarized in Table 1. Among them, we identified
seven (35%) children (mean of age at 8.0± 3.0 years old, Table 1) with significant intestinal inflammation
(fecal calprotectin > 250 µg/g, with levels ranged from 300 to 1800 µg/g). Age of patients, mutation
severities, %BMI and %FEV1 were not significantly different between children without and with
intestinal inflammation (Table 1). In addition, no complaint recorded in questionnaires could
discriminate inflammatory status of children (Table 1). However, children with intestinal inflammation
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have received significantly more intravenous antibiotic courses before inclusion (p = 0.04 adjusted
with age, Table 1).
CF children with intestinal inflammation are distinguished by their intestinal microbiota
composition. The microbiota composition from 20 fecal samples was estimated using targeted 16S
rRNA gene sequencing. After bioinformatic analysis, the median number of high-quality reads
per patient was 421,720 (from 69,534 to 2,500,796). Taxonomic assignment was used to compare
the profiles of patients’ microbiota (Figure 1). At the phylum level, the proportion of Firmicutes
was significantly higher in microbiota profiles of children with intestinal inflammation (on average
81% vs. 65% respectively for children with and without intestinal inflammation, FDR = 0.0078)
(Figure 1A). To evaluate species diversity in patients’ microbiome we calculated alpha diversity indices.
The Shannon and Simpson indices are two complementary approaches to alpha diversity, sensitive to
changes in abundance of the rarest or the most abundant OTUs, respectively. Alpha diversity indexes
were not significantly different between children with and without intestinal inflammation (Figure 1B).
However, the beta diversity analysis (NMDS) reflecting the variation of microbiome between samples,
showed partial separation of the patients with intestinal inflammation (Figure 1C).
Figure 1. Microbiota composition in the Cystic Fibrosis (CF) cohort. (A) Proportions of bacteria
from the five most abundant phyla colored according to the legend. Calprotectin measurements per
patient are shown in boxes below the bar plot. The proportion of Firmicutes was significantly higher in
microbiota profiles of children with intestinal inflammation (gray boxes). (B) Alpha diversity values
for all patients (n = 20) are shown as points and summarized as boxplots for each group. Both Shannon
and Simpson alpha indices measure microbial diversity within sample, and they were not significantly
different between children with and without intestinal inflammation (Wilcoxon—Mann–Whitney test).
(C) Beta diversity (NMDS), which assesses differences in microbial composition between samples using
a NMDS ordination method with Bray–Curtis distance metric, showed a partial separation of samples
of patients with intestinal inflammation.
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Differential expression (DESeq2) analysis revealed 80 distinctive OTUs that belonged to 25 unique
taxonomic nodes differentially present between patients according to their intestinal inflammation
status (Figure 2A, Supplementary Table S2). Among them, increased abundances of Acidaminococcus
spp., Staphylococcus spp., Streptococcus spp., and Veillonella dispar, along with decreased abundances of
Bacteroides spp., Ruminococcus spp., Coprococcus spp., Dialister spp., Parabacteroides spp., Bifidobacterium
spp., Dorea formicigenerans, and Faecalibacterium prausnitzii were observed in children with fecal
calprotectin higher than 250 µg/g (Figure 2A).
Figure 2. The composition of the microbiota differs according to the inflammation status of CF
patients. (A) Differential abundance analysis (DESeq) assessing OTU significantly changed in the
microbiome of patients with intestinal inflammation, compared with patients without intestinal
inflammation. Each circle represents one of 80 significant OTUs colored by a phylum according to the
legend. OTUs are collapsed to 25 taxa represented on x axis and ordered by decreasing log of fold
change. For full results see Supplementary Table S2. (B) LEfSe analysis showing OTUs distinguishing
patients without and with intestinal inflammation (p-value < 0.01) and confirming DESeq2 results.
For full results see Supplementary Table S3.
Using LEfSe analysis (Supplementary Table S3), we identified numerous taxonomic nodes that
can predict intestinal inflammation in our young CF population. It confirmed the results of DESeq2 at
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genus levels regarding Staphylococcus, Streptococcus, Bacteroides, Ruminococcus, Coprococcus, Dialister,
and Parabacteroides, and at the species level regarding Veillonella dispar, Bifidobacterium adolescentis,
Dorea formicigenerans, and Faecalibacterium prausnitzii. In addition, some OTUs belonging to the families
Lachnospiraceae and Ruminococcaceae appear to be differentially correlated to the inflammatory
patient status (Figure 2B, results with p-value < 0.01).
CF intestinal inflammation and microbiota exhibit similarities with IBD. In order to analyze
deeper the CF intestinal microbiota changes in our cohort, we applied the MD-index, recently designed
and validated in CD [32]. This index is based on a ratio between given bacterial taxa known to
be increased or decreased in CD listed in Figure 3A. The MD-index was significantly higher in the
CF children with intestinal inflammation compared to the group without inflammation (p = 0.03)
(Figure 3B and Supplementary Table S4). It was not correlated to age, %BMI, or %FEV1 in our cohort.
Figure 3. MD-index distribution in CF cohort according to the intestinal inflammation status.
(A) Bacterial taxa contributing to the MD-index according to [32]. (B) Boxplot of MD-index values for
patients separated into groups according to calprotectin level. Patients with CF intestinal inflammation
have a significant higher MD-index (Wilcoxon–Mann–Whitney test, p = 0.03). For full results see
Supplementary Table S4.
However, Streptococcus genus, increased in our inflammatory patient group, is not usually
associated with IBD and is not included in the MD-index. Given the role of Streptococcus mitis group in
CF lung disease evolution [33,34] and difficulties in distinguishing this group from other Streptococci
by NGS, we assessed the presence of mitis group species by using ddPCR that specifically targeted
Streptococcus oralis. We observed a non-significant increase log ratios of S. oralis per total bacteria in
children with intestinal inflammation, compared to children with low calprotectin levels (ratio median
−5.8 and −6.8, respectively, p = 0.24) (Figure 4).
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Figure 4. Relative abundance of S. oralis assessed by ddPCR according to the inflammation status
of CF patients. Boxplot of values representing relative proportion of S. oralis in patients’ microbiomes,
separated into groups according to calprotectin level. Among Streptococcus found in CF children,
there was a notable proportion of S. oralis but without significant difference between children with or
without intestinal inflammation (Wilcoxon–Mann–Whitney test, p = 0.24).
Intestinal inflammation at the inclusion is associated with increased antibiotic use over the
next two years. We compared the clinical evolution at two years between children without and with
intestinal inflammation. While intestinal inflammation was not predictive of evolution of %FEV1 or
%BMI at two years (Table 1), children with intestinal inflammation at the inclusion had more antibiotic
treatments over the next two years, all routes of administration combined (p = 0.02). Surprisingly,
this discrepancy appears to be more related to inhaled antibiotic courses (p = 0.02) than to intravenous
(p = 0.06) or oral (p > 0.05) antibiotic therapies (Table 1).
4. Discussion
Intestinal microbiota disturbances and intestinal inflammation are now widely accepted as an
integral part of CF. With the increased life expectancy of patients, the management of these digestive
disorders is becoming a topical subject, even if the corresponding physiological mechanisms are not
yet well understood. In fact, links between intestinal microbiota and inflammation in CF have been
suggested directly or indirectly by a limited number of studies [5]. In one of the few CF studies
analyzing gut microbiota by NGS according to inflammation, intestinal inflammation was associated
with an increase of E. coli abundance [24]. In another study, gastrointestinal mucosal lesions recorded
by capsule endoscopy was positively correlated with Firmicutes and negatively correlated with
Bacteroidetes [3]. Indirectly, probiotic intake or antibiotic courses in CF patients were able to decrease
intestinal inflammation [20,35].
In order to refine the relationships between intestinal microbiota composition and inflammation
in the CF, we compared intestinal microbiota profiles from young CF patients, according to their
intestinal inflammatory status evaluated by fecal calprotectin. Despite the limited number of children
included (n = 20) and their young age (mean of age at 8.0 ± 3.0 y.o. in Table 1), we identified a notable
proportion of children (35%) with significant intestinal inflammation and microbiota disturbances
(Figures 1 and 2). In this group, fecal calprotectin levels ranged from 300 to 1800 µg/g, rates comparable
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to those seen in IBD [26]. We observed increased abundances of Staphylococcus spp., Streptococcus
spp., and Veillonella dispar, along with decreased abundances of Bacteroides spp., Ruminococcus spp.,
Coprococcus spp., Dialister spp., Parabacteroides spp., Bifidobacterium adolescentis, and Faecalibacterium
prausnitzii in children with fecal calprotectin higher than 250 µg/g (Figure 3). We did not find significant
increased E. coli abundances, as previously reported in a cohort of younger CF children (median
age at 10 months) [24]. Our results were confirmed using LEfSe (Supplementary Table S3). On the
whole, these microbiota disturbances exhibited numerous similarities with the well described IBD
microbiota [23,32,36]. Interestingly, the MD-index, which is positively correlated with the clinical
disease activity of CD [32], was significantly higher in our group of CF children with high fecal
calprotectin levels.
Decrease of B. adolescentis and F. prausnitzii in group of children with intestinal inflammation
confirm the results recently published in CF [22] and are congruent with data exploring in vitro
anti-inflammatory proprieties of bacteria. Bifidobacterium adolescentis inhibits inflammatory responses
in intestinal epithelial cells, by limiting the lipopolysaccharide-induced inflammatory response and
the TNF-α production [37]. Furthermore, the intestinal inflammation in our cohort was associated
with an under-representation of F. prausnitzii (Figure 2B), a strain well investigated in IBD for its
anti-inflammatory properties and considered as a viable marker of health [36].
Taken together, these results raise the question of the causal relationship between microbiota
composition and inflammation: does a decrease of anti-inflammatory bacteria lead to inflammation or
does it result from this inflammation as a basic consequence of anti-inflammatory bacteria decrease?
The answer to this question is still a matter of debate in CF as well as IBD [38]. Keeping in mind that the
causal relation is probably bidirectional, few published data suggest the existence of a pro-inflammatory
microbiota. Experiments using a murine model of colitis showed that disease can be transmitted from
a genetically modified mouse to a wild mouse by a microbiota transfer [39]. In CF, oral antibiotic or
probiotic exposures were shown to reduce intestinal inflammation [20,35]. A higher MD-index in
our inflammatory subpopulation lets us suggest that these patients may have a more pronounced
“pro-inflammatory” microbiota (Figures 2A and 3B). This subpopulation exhibited also significantly
more Firmicutes and had previously received more IV antibiotics, which is a known factor leading to
an increase of Firmicutes (Table 1 and Figure 1A) [8]. Moreover, the young age of our cohort together
with the microbiota disturbances observed in CF from the first weeks of life [9,40] seem to indicate that
CF gut microbiota changes is inherent to the disease rather than a basic consequence of inflammation
and/or antibiotic use.
More recently, the human microbiome (which includes the gut microbiome but also the other body
sites) has emerged as a complex interconnected entity leading to the popularization of the concepts of
gut–brain and gut–lung axes [41,42]. The gut–lung axis is of major interest in CF, as patients colonize
their digestive tract with microorganisms from oral or respiratory tracts by sputum swallowing [43].
Bacteria found in gastric fluid were correlated with CF sputum microbiota composition, especially
regarding Streptococcus abundance [43]. Streptococcus isolates are naturally present in the digestive
tract [9] but their proportion seems to be higher in CF patients [9]. We identified a significant
over-representation of Streptococcus spp. in CF children with intestinal inflammation (Figure 3A), with a
notable proportion of S. oralis (Figure 4). Streptococcus strains may contribute to the inflammatory
process by synergistic interactions with other commensal microorganisms such as Candida albicans or
Veillonella spp., both being increased in IBD flares [23,44,45]. Overall, these data support the relationship
between respiratory and digestive microbiomes.
This CF “gut–lung axis” is poorly described. It appears to be bidirectional with intestinal microbiota
changes predicting pulmonary colonization of Pseudomonas aeruginosa [40] and oral probiotics decreasing
pulmonary exacerbations [46]. Interestingly, we found that intestinal inflammation at the inclusion
was associated with an increase in short-term antibiotic cures, especially with an increase over the next
two years in inhaled antibiotic courses (Table 1). However, in the absence of repeated fecal calprotectin
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measurement during these two years, we cannot affirm that non-inflammatory patients at baseline
remain without intestinal inflammation during this period.
Short-term intestinal inflammation may affect the nutritional status of CF patients, as demonstrated
by significant correlations between fecal calprotectin level and both weight z-scores and height z-scores
of CF patients [47]. As previously recorded [21], we did not find a significant correlation between
intestinal inflammation and BMI. BMI evolution is recognized as multifactorial and is now part of the
nutritional management, fully integrated into CF disease treatment [21].
Long-term inflammation could impact morbidity and mortality, especially regarding the increased
risk of small intestine and colon cancers in CF patients compared with the general population [48].
The pathogenesis of digestive cancers in CF remains unclear. It has been shown that chronic intestinal
inflammation is associated with this malignancy risk [49]. Furthermore in IBD, risk factor for colorectal
cancer is correlated with the intensity and duration of the inflammation [50]. CF inflammation is present
even at an early age, as well demonstrated in our pediatric cohort than in previous studies [51,52],
which may be a key factor in developing digestive malignancy later on.
Microbiota composition has also been associated with digestive cancer, due to a decrease in
bacteria protecting against cancer and changes in the corresponding metabolite production, such as a
decrease in butyrate production, also observed in CF patients with intestinal inflammation [49,53,54].
We and others [10,22,40,54,55] showed that Bacteroides—known as protective bacteria against
malignancy [53]—are decreased in CF.
5. Conclusions
To conclude, with more CF patients surviving into advanced adulthood we need to improve our
understanding and management of this systemic disease, including the chronic intestinal inflammation.
Few studies including ours reinforce the relation between intestinal inflammation and microbiota
disturbance. Further in vitro and in vivo studies are warranted given the limited understanding of
the CF physiopathology. Even well-documented probiotic strains, such as Bifidobacterium adolescentis
identified in this study to be significantly decreased—that inhibits inflammatory responses in intestinal
epithelial cells [37]—will require further clinical trials to decipher their potential ability to reduce the
short-term intestinal inflammation and the long-term cancer risk.
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